BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 35061935)

  • 1. Multi-omics analysis of intra-tumoural and inter-tumoural heterogeneity in pancreatic ductal adenocarcinoma.
    Liu X; Wang W; Liu X; Zhang Z; Yu L; Li R; Guo D; Cai W; Quan X; Wu H; Dai M; Liang Z
    Clin Transl Med; 2022 Jan; 12(1):e670. PubMed ID: 35061935
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inter- and intra-tumoural heterogeneity in cancer-associated fibroblasts of human pancreatic ductal adenocarcinoma.
    Neuzillet C; Tijeras-Raballand A; Ragulan C; Cros J; Patil Y; Martinet M; Erkan M; Kleeff J; Wilson J; Apte M; Tosolini M; Wilson AS; Delvecchio FR; Bousquet C; Paradis V; Hammel P; Sadanandam A; Kocher HM
    J Pathol; 2019 May; 248(1):51-65. PubMed ID: 30575030
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Single-cell transcriptome analysis of tumor and stromal compartments of pancreatic ductal adenocarcinoma primary tumors and metastatic lesions.
    Lin W; Noel P; Borazanci EH; Lee J; Amini A; Han IW; Heo JS; Jameson GS; Fraser C; Steinbach M; Woo Y; Fong Y; Cridebring D; Von Hoff DD; Park JO; Han H
    Genome Med; 2020 Sep; 12(1):80. PubMed ID: 32988401
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Single-cell RNA-seq highlights intra-tumoral heterogeneity and malignant progression in pancreatic ductal adenocarcinoma.
    Peng J; Sun BF; Chen CY; Zhou JY; Chen YS; Chen H; Liu L; Huang D; Jiang J; Cui GS; Yang Y; Wang W; Guo D; Dai M; Guo J; Zhang T; Liao Q; Liu Y; Zhao YL; Han DL; Zhao Y; Yang YG; Wu W
    Cell Res; 2019 Sep; 29(9):725-738. PubMed ID: 31273297
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gene expression profiling of 1200 pancreatic ductal adenocarcinoma reveals novel subtypes.
    Zhao L; Zhao H; Yan H
    BMC Cancer; 2018 May; 18(1):603. PubMed ID: 29843660
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma.
    Qian Y; Gong Y; Fan Z; Luo G; Huang Q; Deng S; Cheng H; Jin K; Ni Q; Yu X; Liu C
    J Hematol Oncol; 2020 Oct; 13(1):130. PubMed ID: 33008426
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High overall copy number variation burden by genome-wide methylation profiling holds negative prognostic value in surgically treated pancreatic ductal adenocarcinoma.
    Detlefsen S; Boldt HB; Burton M; Thomsen MM; Rasmussen LG; Ørbeck SV; Pfeiffer P; Mortensen MB; de Stricker K
    Hum Pathol; 2023 Dec; 142():68-80. PubMed ID: 37977512
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SCNrank: spectral clustering for network-based ranking to reveal potential drug targets and its application in pancreatic ductal adenocarcinoma.
    Liu E; Zhang ZZ; Cheng X; Liu X; Cheng L
    BMC Med Genomics; 2020 Apr; 13(Suppl 5):50. PubMed ID: 32241274
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High methylation levels of PCDH10 predict poor prognosis in patients with pancreatic ductal adenocarcinoma.
    Curia MC; Fantini F; Lattanzio R; Tavano F; Di Mola F; Piantelli M; Battista P; Di Sebastiano P; Cama A
    BMC Cancer; 2019 May; 19(1):452. PubMed ID: 31088413
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Deciphering the Prognostic Implications of the Components and Signatures in the Immune Microenvironment of Pancreatic Ductal Adenocarcinoma.
    Tang R; Liu X; Liang C; Hua J; Xu J; Wang W; Meng Q; Liu J; Zhang B; Yu X; Shi S
    Front Immunol; 2021; 12():648917. PubMed ID: 33777046
    [No Abstract]   [Full Text] [Related]  

  • 11. Single-cell RNA-seq reveals dynamic change in tumor microenvironment during pancreatic ductal adenocarcinoma malignant progression.
    Chen K; Wang Q; Li M; Guo H; Liu W; Wang F; Tian X; Yang Y
    EBioMedicine; 2021 Apr; 66():103315. PubMed ID: 33819739
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Impact of Immune Microenvironment on the Prognosis of Pancreatic Ductal Adenocarcinoma Based on Multi-Omics Analysis.
    Yang B; Zhou M; Wu Y; Ma Y; Tan Q; Yuan W; Ma J
    Front Immunol; 2021; 12():769047. PubMed ID: 34777388
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The CTCF/LncRNA-PACERR complex recruits E1A binding protein p300 to induce pro-tumour macrophages in pancreatic ductal adenocarcinoma via directly regulating PTGS2 expression.
    Liu Y; Wang X; Zhu Y; Cao Y; Wang L; Li F; Zhang Y; Li Y; Zhang Z; Luo J; Deng X; Peng C; Wei G; Chen H; Shen B
    Clin Transl Med; 2022 Feb; 12(2):e654. PubMed ID: 35184402
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Single-cell RNA-seq analysis reveals BHLHE40-driven pro-tumour neutrophils with hyperactivated glycolysis in pancreatic tumour microenvironment.
    Wang L; Liu Y; Dai Y; Tang X; Yin T; Wang C; Wang T; Dong L; Shi M; Qin J; Xue M; Cao Y; Liu J; Liu P; Huang J; Wen C; Zhang J; Xu Z; Bai F; Deng X; Peng C; Chen H; Jiang L; Chen S; Shen B
    Gut; 2023 May; 72(5):958-971. PubMed ID: 35688610
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel hotspot and rare somatic mutation p.A138V, at TP53 is associated with poor survival of pancreatic ductal and periampullary adenocarcinoma patients.
    Saha G; Singh R; Mandal A; Das S; Chattopadhyay E; Panja P; Roy P; DeSarkar N; Gulati S; Ghatak S; Ghosh S; Banerjee S; Roy B; Ghosh S; Chaudhuri D; Arora N; Biswas NK; Sikdar N
    Mol Med; 2020 Jun; 26(1):59. PubMed ID: 32552660
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of key regulators of pancreatic cancer progression through multidimensional systems-level analysis.
    Rajamani D; Bhasin MK
    Genome Med; 2016 May; 8(1):38. PubMed ID: 27137215
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PTEN alterations of the stromal cells characterise an aggressive subpopulation of pancreatic cancer with enhanced metastatic potential.
    Wartenberg M; Centeno I; Haemmig S; Vassella E; Zlobec I; Galván JA; Neuenschwander M; Schlup C; Gloor B; Lugli A; Perren A; Karamitopoulou E
    Eur J Cancer; 2016 Sep; 65():80-90. PubMed ID: 27475963
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined Analysis of the Aberrant Epigenetic Alteration of Pancreatic Ductal Adenocarcinoma.
    Xu R; Xu Q; Huang G; Yin X; Zhu J; Peng Y; Song J
    Biomed Res Int; 2019; 2019():9379864. PubMed ID: 31956659
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Copy Number Variations in Pancreatic Cancer: From Biological Significance to Clinical Utility.
    Oketch DJA; Giulietti M; Piva F
    Int J Mol Sci; 2023 Dec; 25(1):. PubMed ID: 38203561
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Proteogenomic insights into the biology and treatment of pancreatic ductal adenocarcinoma.
    Tong Y; Sun M; Chen L; Wang Y; Li Y; Li L; Zhang X; Cai Y; Qie J; Pang Y; Xu Z; Zhao J; Zhang X; Liu Y; Tian S; Qin Z; Feng J; Zhang F; Zhu J; Xu Y; Lou W; Ji Y; Zhao J; He F; Hou Y; Ding C
    J Hematol Oncol; 2022 Nov; 15(1):168. PubMed ID: 36434634
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.